A human-specific switch of alternatively spliced AFMID isoforms contributes to TP53 mutations and tumor recurrence in hepatocellular carcinoma

Genome Res. 2018 Mar 1;28(3):275-284. doi: 10.1101/gr.227181.117.

Abstract

Pre-mRNA splicing can contribute to the switch of cell identity that occurs in carcinogenesis. Here, we analyze a large collection of RNA-seq data sets and report that splicing changes in hepatocyte-specific enzymes, such as AFMID and KHK, are associated with HCC patients' survival and relapse. The switch of AFMID isoforms is an early event in HCC development and is associated with driver mutations in TP53 and ARID1A The switch of AFMID isoforms is human-specific and not detectable in other species, including primates. Finally, we show that overexpression of the full-length AFMID isoform leads to a higher NAD+ level, lower DNA-damage response, and slower cell growth in HepG2 cells. The integrative analysis uncovered a mechanistic link between splicing switches, de novo NAD+ biosynthesis, driver mutations, and HCC recurrence.

MeSH terms

  • Alternative Splicing*
  • Arylformamidase / genetics
  • Arylformamidase / metabolism
  • Carcinoma, Hepatocellular* / genetics
  • Carcinoma, Hepatocellular* / pathology
  • DNA-Binding Proteins / genetics
  • DNA-Binding Proteins / metabolism
  • Gene Expression Regulation, Neoplastic
  • Hep G2 Cells
  • Humans
  • Liver Neoplasms* / genetics
  • Liver Neoplasms* / pathology
  • Mutation*
  • NAD / metabolism
  • Neoplasm Recurrence, Local* / genetics
  • Protein Isoforms / genetics
  • Transcription Factors / genetics
  • Transcription Factors / metabolism
  • Tumor Suppressor Protein p53* / genetics
  • Tumor Suppressor Protein p53* / metabolism

Substances

  • ARID1A protein, human
  • DNA-Binding Proteins
  • NAD
  • Protein Isoforms
  • TP53 protein, human
  • Transcription Factors
  • Tumor Suppressor Protein p53
  • Arylformamidase